Life Sciences Ontario (LSO) recognized Satellos as the Company of the Year as part of their 2024 LSO Awards, recognizing outstanding individuals and companies contributing to the success of Ontario’s life sciences sector. The award was presented during LSO’s Celebration of Success Awards Presentation on Wednesday, May 15th at the Liberty Grand, Exhibition Place, Toronto.
The LSO Awards are an important part of the organization’s goal to advocate for Ontario’s life sciences sector, by celebrating the individuals and companies behind its success.
“Recognizing the incredible achievements of these recipients highlights the diverse talents and contributions within our dynamic life sciences community,” says Dr. Jason Field, President & CEO of Life Sciences Ontario. “Their dedication and innovation continue to elevate Ontario as a hub for excellence in the sector.”
Life Sciences Ontario (LSO) is a member-funded, not-for-profit organization with a legacy of more than 30 years advancing the success of Ontario’s life sciences sector. LSO collaborates with government, academia, industry, and other life sciences organizations in Ontario and across Canada to promote and encourage commercial success throughout the sector.
“We’re honored that Satellos has been named Company of the Year by Life Sciences Ontario for our breakthrough work in advancing a novel small molecule drug candidate with the potential to promote muscle repair and regeneration and be a disease-modifying treatment for Duchenne muscular dystrophy,” said Frank Gleeson, Cofounder and CEO, Satellos. “We are proud of the hard work from the team and look forward to beginning our first-in-human clinical trials for SAT-3247 this year.”
Learn more about the 2024 LSO Awards here.
